Jennerex Biotherapeutics: Products - JX

Jennerex’s lead product candidate, JX-594, is based on the vaccinia virus strain which is uniquely suited to treat cancers. JX-594 is genetically modified by deleting its thymidine kinase gene to enhance cancer-selectivity. In addition, it has been armed with GM-CSF gene to stimulate systemic anti-tumoral immune response in the context of product replication and lysis of the infected cancer cells. It is designed to destroy both injected and non-injected metastatic tumors. This virus was engineered from the strain of vaccinia virus that is the basis for the vaccine that has been used in hundreds of millions of people in vaccination against smallpox.

Worth checking out